Entering text into the input field will update the search result below

Apheresis Market Worth $2.7 Billion By 2025

Jan. 28, 2021 8:43 AM ETTerumo Corporation (TRUMF), FSNUF, HAE, AHKSF, BAX, CERS, KANKF
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • New Indications for Plasma Products.
  • Increasing Number of Collaborations, Agreements, and Partnerships.

Market Size Estimation:

The apheresis market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and top-down approach (assessment of utilization/adoption/penetration trends, by product, technology, application, procedure, end user, and region).

What the Market Looks Like?

The global apheresis market is expected to reach USD 2.7 billion by 2025 from an estimated value of USD 1.7 billion in 2019, growing at a CAGR of 8.1% during the forecast period.

Data Triangulation:

After arriving at the market size, the total apheresis market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Critical questions the report answers:

# Where will these developments take the industry in the mid-to-long term?

# Who are the major end users in the apheresis market, and what are the benefits they avail by implementing apheresis technology?

# What are the recent trends in the apheresis market?

# What are the major market dynamics and their impact on overall market growth?

# What is the global scenario of the apheresis market?

Download PDF Brochure @ Apheresis Market

Recent Developments:

# In July 2019, Baxter International Inc. (US) launched the PrisMax system in the US.

# In June 2019, Toray Medical Co. Ltd. (Japan) launched the TORAMYXIN device in the European region.

# In October 2019, Terumo BCT (US) collaborated with the UniCAR-Therapy Bio-Medicine Technology Co. (CHINA). This collaboration aimed at advancing CAR T-cell therapies by creating a new Shanghai Center of Excellence. This development also helped Terumo widen its applications of apheresis and leukapheresis procedures.

# In August 2017, Fresenius Medical Care (Germany) acquired NxStage Medical, Inc. (US). This acquisition enabled Fresenius Medical Care to further expand its presence in the renal care and critical care area.

North America accounted for the largest market share in 2018

North America accounted for the largest share of the apheresis market in 2018, followed by Europe. The large share of this region can be attributed to easier accessibility to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.

Request Sample Pages@ Apheresis Market

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.